Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those affected by AMD. Together, TLI and AMDF are dedicated to advancing awareness, ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Tina Patel, contact lens optician at Feel Good Contacts, has warned smokers around the UK, with AMD currently affecting more ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

The company offers year-round educational services on the conditions, using this month, in particular, to guide patients to ...

Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...